English

CS MEDICA Greenlights Establishment of CANNORDIC India Pvt. Ltd. as Part of Global Expansion Strategy

Report this content

CS MEDICA A/S (“CS MEDICA” or the “Company”), a MedTech company specialized in Cannabis and pain management, is pleased to announce the establishment of CANNORDIC India Pvt. Ltd. in India. The company has received approval from its board of directors to set up the subsidiary with the purpose of getting the CANNASEN products approved in India for marketing and sales.

CS MEDICA, a global MedTech company specialized in Cannabis and pain management, announces today the approval by its Board of Directors to establish a subsidiary in India, CANNORDIC India Pvt. Ltd., with the aim of obtaining approval from Indian regulatory authorities for marketing and sales of its CANNASEN® product line. This strategic move is in line with CS MEDICA's commitment to expanding its global presence and offering innovative solutions to customers worldwide. India is a key market for the company, and the establishment of CANNORDIC India Pvt. Ltd. will enable CS MEDICA to introduce its renowned CANNASEN products to the Indian market.

CS MEDICA's product-line under the trademark, CANNASEN®, provides efficient and safe over-the-counter (OTC) alternative treatments for autoimmune and stress-related disorders. Leveraging their expertise in research, development, manufacturing, and commercialization, CS MEDICA is well-positioned to make a significant impact in the Indian MedTech space. This strategic move reinforces CS MEDICA's commitment to delivering high-quality medical solutions and addressing the healthcare needs of patients in India and beyond.

The board of directors has appointed Lone Henriksen and Kamlesh Vora as Directors of the Indian company.

"We are thrilled to introduce our CANNASEN products to the Indian market, which presents significant opportunities for our company. With the appointment of Kamlesh Vora as the Managing Director of CANNORDIC India Pvt Ltd, we have a seasoned leader who brings a wealth of experience to guide us through the complex regulatory landscape and successfully launch our products", says Lone Henriksen, CS MEDICA's Chief Executive Officer.

CANNORDIC India Pvt. Ltd. is dedicated to working in close partnership with local collaborators to ensure compliance with all regulatory requirements, facilitating timely availability of their products to customers. The company also aims to explore potential avenues for expanding its product portfolio in India, thereby making a positive contribution to the growth and advancement of the Indian pharmaceutical industry.

“As the Managing Director of CS MEDICA's Indian subsidiary, I am thrilled to announce our expansion into the Indian market. With our expertise in MedTech and CBD-based medical devices, we are excited to bring our innovative products to India and provide safe and effective treatment options for patients suffering from autoimmune and stress-related disorders. Our commitment to combining science and nature aligns perfectly with the needs of the Indian market, and we are eager to submit our applications for registration with CDSCO[1]. We look forward to making a positive impact on healthcare in India and creating new opportunities for patients in need.”, says Kamlesh Vora, Managing Director of CANNORDIC India Pvt Ltd.

[1] CDSCO stands for Central Drugs Standard Control Organization. It is the national regulatory authority in India responsible for the regulation and control of pharmaceuticals, medical devices, cosmetics, and diagnostics. CDSCO operates under the Ministry of Health and Family Welfare and is responsible for ensuring the safety, efficacy, and quality of drugs and medical devices in India through regulatory approvals, licensing, inspections, and other regulatory functions.


For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish-based MedTech company operating within research, development, manufacturing, commercializing, and a part of the pharmaceutical industry. The company combines science and nature with the purpose of creating products for a better every day by using modern technology to research and utilize different compounds found in the cannabis plant. CS MEDICA offers efficient, safe OTC alternative treatments for autoimmune and stress-related disorders under the trademark CANNASEN® or own label options.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). more information, visit cs-medica.com, and LinkedIn.

Tags:

India medical device CBD CANNASEN cannabisindustri marketexpansion

Subscribe

Documents & Links

Quotes

We are thrilled to introduce our CANNASEN products to the Indian market, which presents significant opportunities for our company. With the appointment of Kamlesh Vora as the Managing Director of CANNORDIC India Pvt Ltd, we have a seasoned leader who brings a wealth of experience to guide us through the complex regulatory landscape and successfully launch our products.
Lone Henriksen, CEO at CS MEDICA
As the Managing Director of CS MEDICA's Indian subsidiary, I am thrilled to announce our expansion into the Indian market. With our expertise in MedTech and CBD-based medical devices, we are excited to bring our innovative products to India and provide safe and effective treatment options for patients suffering from autoimmune and stress-related disorders. Our commitment to combining science and nature aligns perfectly with the needs of the Indian market, and we are eager to submit our applications for registration with CDSCO[1]. We look forward to making a positive impact on healthcare in India and creating new opportunities for patients in need.
Kamlesh Vora, Managing Director of CANNORDIC India Pvt Ltd.